Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Adrian F. Ochsenbein, Martin Früh et al.|Clinical Lung Cancer|2016Cited by 10
MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)Sacha I. Rothschild, R. Jaggi, Matthias Amrein et al.|Journal of Thoracic Oncology|2017Cited by 1
PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09)Sacha I. Rothschild, Rolf Jaggi, Oliver Gautschi et al.|Journal of Thoracic Oncology|2017Cited by 0